Dacomitinib
- Generic Name
- Dacomitinib
- Brand Names
- Vizimpro
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25ClFN5O2
- CAS Number
- 1110813-31-4
- Unique Ingredient Identifier
- 2XJX250C20
- Background
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains.
...
- Indication
Dacomitinib is indicated as the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as verified by an FDA-approved test.
...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 35
- Registration Number
- NCT02039336
- Locations
- 🇳🇱
Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands
🇳🇱The Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱University Medical Center Utrecht, Utrecht, Netherlands
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2013-08-09
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 110
- Registration Number
- NCT01920061
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Medical University of South Carolina/ University Hospital, Charleston, South Carolina, United States
🇺🇸MUSC Health East Cooper, Mount Pleasant, South Carolina, United States
A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT01858389
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸Investigational Drug Service, Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2016-06-13
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 12
- Registration Number
- NCT01737008
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis
- First Posted Date
- 2012-11-19
- Last Posted Date
- 2021-05-14
- Target Recruit Count
- 32
- Registration Number
- NCT01728233
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment
- Conditions
- Interventions
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT01571388
- Locations
- 🇺🇸
Pfizer Investigational Site, South Miami, Florida, United States
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
- Conditions
- Interventions
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 236
- Registration Number
- NCT01465802
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸St. Jude Heritage Healthcare, Fullerton, California, United States
🇺🇸UC San Diego Medical Center - La Jolla, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.